1. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study
- Author
-
G. Creatsas, D. Quail, T. Rechberger, Herman Depypere, Mithat Erenus, J. Bonnar, Thomas Nickelsen, and T. Arndt
- Subjects
medicine.medical_specialty ,Norethisterone ,business.industry ,Cholesterol ,medicine.medical_treatment ,Obstetrics and Gynecology ,Hormone replacement therapy (menopause) ,General Medicine ,Placebo ,Norethisterone acetate ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Selective estrogen receptor modulator ,Internal medicine ,medicine ,lipids (amino acids, peptides, and proteins) ,Raloxifene ,business ,medicine.drug ,Lipoprotein - Abstract
Objective To compare the effects of the selective estrogen receptor modulator (SERM) raloxifene (Evista®) and a continuous combined hormone replacement therapy (ccHRT) formulation containing estradiol and norethisterone acetate (Kliogest®) on lipid and fibrinogen levels of postmenopausal women. Methods Euralox 1 was a prospective, randomized, double-blind trial. After a placebo wash-out, healthy postmenopausal women (n = 1008, average age 56.1 ± 4.9 years) with a health risk profile that suggested a potential benefit from either treatment were randomly assigned to either 60 mg raloxifene or ccHRT consisting of 2 mg estradiol and 1 mg norethisterone acetate (NETA) per day for 6 months. Measurements Total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol with its fractions HDL2 and HDL3, the LDL/HDL ratio, triglycerides and fibrinogen were asessed at baseline and after 6 months or on early drop-out. Results Baseline values were comparable between the two grou...
- Published
- 2001
- Full Text
- View/download PDF